Skip to Main Content

Antonio Omuro, MD

Professor of Neurology; Chief, Neuro-Oncology; Director, Chenevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center

Research Summary

Dr. Omuro is an international leader in the research of brain tumors, having led pivotal research programs and clinical trials to advance the treatment of these difficult cancers.

Extensive Research Description

Dr. Omuro is an international leader in the research of brain tumors, having led pivotal research programs and clinical trials to advance the treatment of these difficult cancers.


Coauthors

Research Interests

Glioblastoma; Meningeal Neoplasms; Clinical Trial; Central Nervous System Neoplasms

Selected Publications

Clinical Trials

ConditionsStudy Title
Brain and Nervous SystemA Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1
Brain and Nervous System; PediatricsA Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
Brain and Nervous SystemA Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
Brain and Nervous SystemGBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Brain and Nervous SystemPhase 1: BGB-290 in combination with TMZ in patients w/ IDH1/2-mutant WHO grade II-IV recurrent glioma: Phase 2: Grade II-III patients in will be stratified into 2 arms based on the timing of prior alkylator chemotherapy exposure; a third arm will include the subset of glioblastoma (grade IV) patients
Brain and Nervous SystemGenomically-Guided Treatment Trial in Brain Metastases
Brain and Nervous SystemPhase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Brain and Nervous SystemPhase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Brain and Nervous SystemPhase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Brain and Nervous System; PediatricsA Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma